idelalisib for relapsed/refractory fl
Published 4 years ago • 16 plays • Length 2:52Download video MP4
Download video MP3
Similar videos
-
8:20
idelalisib for follicular lymphoma
-
3:52
idelalisib’s value in follicular lymphoma
-
4:05
selecting therapy for relapsed-refractory dlbcl
-
1:40
options for treating relapsed/refractory follicular lymphoma
-
4:59
high-risk fl: optimizing approaches with idelalisib
-
4:51
idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory cll
-
4:11
understanding the trial with idelalisib and rituximab
-
3:40
pi3k inhibitors for relapsed/refractory fl
-
3:56
treatment approaches to relapsed/refractory fl
-
1:19
a study of duvelisib vs ofatumumab in relapsed/refractory cll
-
0:56
analyzing challenges in treating patients with relapsed/refractory follicular lymphoma
-
2:31
copanlisib as a treatment for patients with relapsed/refractory indolent b-cell lymphoma
-
2:54
selecting therapy for relapsed-refractory dlbcl
-
1:56
phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory cll
-
6:15
therapy for relapsed follicular lymphoma
-
6:01
gadolin trial: relapsed/refractory follicular lymphoma
-
1:05
current salvage therapy options for relapsed/refractory cll
-
7:14
idelalisib combination therapy in relapsed or treatment-resistant cll better than standard regimen
-
2:48
pi3k/anti-cd20 therapy for relapsed/refractory cll